Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
3
×
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
3
×
san francisco blog main
san francisco top stories
fda
akcea therapeutics
allergan
alnylam pharmaceuticals
andrew fire
blueprint medicines
boston
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
clinical data
companion diagnostic
craig mello
detroit blog main
detroit top stories
dna sequencing
drugs
entrectinib
express scripts
foundation medicine
genfit
gilead sciences
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
intercept pharmaceuticals
What
approved
3
×
drug
medicine
3
×
fda
new
afternoon
alnylam
alnylam’s
cancer
data
deeper
disease
dna
fatty
fingerprint
genetic
gets
going
history
horizon
intercept
known
landmark
liver
making
marketed
matter
nash
nd
nonalcoholic
ok
oks
onpattro
patisiran
pharmaceuticals
rnai
second
specifically
steatohepatitis
targets
Language
Current search:
approved
×
medicine
×
" boston blog main "
×
" san diego top stories "
×
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
